BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Mesh Bio to extend advance digital preventive healthcare in Indonesia

17 March 2023 | News

Mesh Bio partners with Indonesia's PT Pramita to implement predictive analytics software to advance diagnostic services across more than 30 centres in Indonesia

Singapore-based Mesh Bio, a digital health deep tech startup transforming chronic disease management through predictive analytics, and leading diagnostics services provider in Indonesia, PT Pramita (Pramita) have entered a regional partnership to deliver predictive analytics-powered medical check-ups and preventive health services in Indonesia.

In a mutual commitment to address the healthcare burden of an ageing population with rising chronic diseases and healthcare costs, the partnership strives to drive positive health outcomes through digital transformation of medical check ups and preventive health services.

The Memorandum of Understanding (MoU) was signed by Dr Andrew Wu, Co-Founder and CEO of Mesh Bio and Dr Nabil Fachliansyah, Vice President of PT Pramita. It was witnessed by Singapore Minister for Trade & Industry Gan Kim Yong and Indonesian Coordinating Minister for Economic Affairs Airlangga Hartarto as part of the Singapore-Indonesia Leaders' Retreat held in Singapore.

Indonasian population are majory affected by 5 chronic diseases related to high systolic blood pressure, high fasting plasma glucose, high BMI and more leading to risk factors such as chronic conditions as diabetes, obesity and hypertension. Government has thus identified the impetus to manage the burden of non-communicable diseases underurgent health policy concerns. The partnership between Mesh Bio and Pramita aims to address this through the use of Mesh Bio's proprietary software – DARA Health Intelligence Platform.

DARA improves patient engagement and health outcomes by providing actionable health insights through personalised disease risk and adverse event predictions. This first-in-class solution will be rolled out in Indonesia for the first time and enable precision patient intervention to be delivered to a large population in an affordable and scalable manner.